Since the 1950s, dengue has been endemic in Southeast Asia, where DHF/DSS was first recognized. Today, DHF/DSS remains one of the 10 leading causes of hospitalization and is the leading cause of childhood mortality in several Asian countries [3] . Before the 1980s, only sporadic cases of DHF/DSS had been reported in the Americas, but in 1981, an outbreak of DHF/DSS in Cuba marked the introduction of severe dengue cases to the Americas [3, 4] . Since then, cases of DHF/DSS have been reported in this region nearly every year. Recent data show that by August 2001, more than 250,000 cases of dengue and 3,788 cases of DHF/DSS were reported to the World Health Organization. All four dengue serotypes circulated in the region during this period. Brazil is the leading country in absolute number of dengue cases and has the highest incidence rate of the disease, but Colombia is the country with the highest rate of DHF/DSS [5] .
Viruses and vectors
Dengue viruses (dengue-1, dengue-2, dengue-3, and dengue-4), belong to the genus Flavivirus, family Flaviviridae [6] . They consist of a protein and lipid envelope surrounding a single-stranded, positive-sense RNA genome of approximately 11 kb. The order of the proteins encoded by the genome is 5Ј-C-prM(M)-E-NS1-NS2A-NS2B-NS3-NS4A-NS4B-NS5-3Ј. The structural proteins consist of a nucleocapsid or core protein (C), a membrane-associated protein (M) found in glycosylated form in the immature virions (prM), and an envelope protein (E). The nonstructural proteins (NS) include seven proteins (NS1-NS5), some involved in viral replication [7] . Infection starts with the virus binding to its cellular receptor, initially identified as a highly sulfated type of heparan sulfate [8] and confirmed by virusbinding assays [9] . Binding to cells has been shown mediated mainly by domain III of the envelope protein.
Crill and Roehrig [10] used envelope protein-specific monoclonal antibodies to block virus adsorption, and monoclonal antibodies directed to domain III of E glycoprotein were the strongest blockers. Another study showing that dengue viruses are able to bind to cells lacking glycosaminoglycans challenges the exclusive importance of domain III of envelope protein on viral adsorption [11] . Penetration occurs by endocytosis, and once inside the cells, the uncoating of the nucleocapsid is accomplished by an acid-dependent fusion of the viral envelope to the endosomal membrane [12••] . As soon as the uncoating is complete, the viral genome is translated into viral proteins used in the viral RNA replication and assembly of the virus particles [7] .
Dengue viruses are transmitted primarily by the female of the Aedes aegypti mosquitoes, but transmission has also been associated with other Aedes species, especially Aedes albopictus [13] .
Clinical manifestations
Dengue virus infections may be asymptomatic or may lead to a wide range of manifestations, including an undifferentiated fever, classic dengue fever, or DHF with plasma leakage that may lead to hypovolemic shock, or DSS [14] .
The clinical manifestations of dengue fever depend on the age of the patient. Infants and young children, especially those younger than 15 years, may have an undifferentiated febrile disease that may be accompanied by a maculopapular rash. After an incubation period of 4 to 7 days, older children and adults will seek treatment with either a mild febrile illness or an incapacitating disease characterized by a high fever of abrupt onset, severe frontal headache, retro-ocular pain, muscle and joint pain, rash, nausea and vomiting, diarrhea, abdominal pain, malaise, and lymphadenopathy. Epistaxis, petechiae, gingival bleeding, hematuria, and menorrhagia are not uncommon. Leukopenia (commonly caused by a neutropenia) and lymphocytosis are usually seen, and a moderate thrombocytopenia may be observed. It is important to differentiate cases of dengue fever with unusual bleeding from cases of DHF/DSS in which the increased vascular permeability and hemoconcentration are the prominent features. The febrile and painful period of dengue fever usually lasts 5 to 7 days, with the appearance of another rash by the end of this period. Recovery may be associated with prolonged fatigue and depression, especially in adults.
Dengue hemorrhagic fever and DSS are the most severe manifestations of dengue infections. They are predominantly a children's disease in Southeast Asia, whereas in the Americas, they are seen in all age groups. The clinical manifestations do not change depending on age group, and DHF usually begins with a sudden rise in temperature and other symptoms that are virtually identical to those of dengue fever. The temperature is high (> 39°C) and remains so for 2 to 7 days. The most common hemorrhagic features are petechiae, easy bruising, and bleeding at venepuncture sites. Epistaxis and gingival bleeding are uncommon, and gastrointestinal bleeding may be observed in severe cases. Hepatomegaly and splenomegaly may be found in some cases, especially in infants. Pleural effusion and ascitis may also be detected and may predict the development of DSS. A progressive decrease in platelet count and rise in the hematocrit are warning signs for the development of DSS. Intense abdominal pain is a frequent complaint that appears shortly before the onset of shock. Patients with DSS have a weak pulse with narrowing blood pressure (Յ 20 mm Hg) and hypotension with cold, clammy skin. Patients may progress to a stage of frank shock, with the blood pressure or pulse becoming imperceptible. The duration of the shock is short. The patient usually dies within the first 24 hours of shock or recovers rapidly after appropriate fluid replacement. The prognosis of DHF/DSS depends on early recognition of DSS cases and adequate treatment of shock. Uncorrected shock will result in a complicated course, with development of metabolic acidosis, severe bleeding from the gastrointestinal tract and other organs, and a poor prognosis. Recovery from adequately treated DSS is short and uneventful, occurring within 2 to 5 days, although pleural effusions and ascites may be detected for a little longer. The course of DHF/DSS is approximately 7 to 10 days, and there usually is no prolonged fatigue.
Dengue infections may also show unusual symptoms such as neurologic manifestations, cardiomyopathy, and intense liver damage [15, 16] . Vertical transmission of dengue viruses has been reported in a small number of cases, leading to neonatal dengue fever or even DSS [17] . Studies of dengue infections during pregnancy have yielded contradictory results. Some authors have reported an increased incidence of neural tube defects in newborns whose mothers were infected during the first trimester of pregnancy. Also, spontaneous abortion during the acute phase of serologically confirmed dengue infections has been reported from Tahiti and Puerto Rico. Several other studies have not found any difference in adverse outcomes of pregnancy in infected pregnant women and healthy control subjects [15] .
Pathogenesis of dengue hemorrhagic fever/dengue shock syndrome
The pathogenesis of dengue fever is not understood completely, and the sites of dengue replication in humans have not been well characterized, although most of the evidence points to the monocyte-macrophage lineage in the lymphoid organs, lung, and liver of patients with dengue infection [18] . Live virus or virus antigens have not been detected on the skin lesions, suggesting that the rash associated with dengue fever is immune mediated and not associated with any direct viral effect.
The main pathophysiologic features of DHF/DSS are (1) increased vascular permeability resulting in loss of plasma from the vascular compartment, leading to hemoconcentration and shock; and (2) a disorder of the homeostasis involving vascular changes, thrombocytopenia, and coagulopathy [3] .
Several hypotheses have attempted to explain DHF/DSS findings, but the lack of an animal model for DHF/DSS has made it difficult to clarify the steps involved in DHF/DSS pathogenesis. Molecular mimicry leading to an autoimmune reaction has been proposed as a cause of DHF/DSS because of the homology of a 20-amino acid sequence in the envelope protein to plasminogen [19, 20] . A viral virulence hypothesis states that certain genotypes of dengue virus are more virulent and more likely to cause severe disease. This hypothesis is supported by the observation that most cases of DHF/DSS in the Americas have been associated with a dengue-2 genotype originating in Southeast Asia [21] . Virulent strains would infect a higher number of cells and produce a higher number of progeny viruses, resulting in a more potent activation of the immune system and a severe inflammatory response that would lead to DHF/DSS. Halstead [22] proposed that the immunopathologic basis of DHF/DSS was the presence of heterotypic nonneutralizing antibodies during the course of secondary infections, resulting in an increased number of dengue virus-infected mononuclear cells. This hypothesis was based on epidemiologic observations performed in Thailand, where DHF/DSS occurred predominantly in children experiencing a secondary infection with a dengue serotype different from the one responsible for the primary infection [23] . DHF/DSS pathogenesis probably involves all of these factors. Vaughn et al. [24] report that, in a study of 168 Thai children, high viremia titer, dengue-2 serotype, and secondary infections were associated with increased severity of the disease. Rothman and Ennis [25] have proposed a more comprehensive hypothesis for DHF/DSS immunopathogenesis. They suggest that the cause of plasma leakage in secondary dengue infections is the synergistic effects of interferon-␥, tumor necrosis factor-␣, and activated complement proteins on endothelial cells throughout the body. They also consider several steps in immunopathologic events. At the earliest stages of dengue infections, preformed dengue virus-specific antibodies increase the number of virus-infected monocytes. As a result, the number of cells presenting dengue viral antigens to T lymphocytes is increased. In the middle stages of infection, the level of T-lymphocyte activation is markedly increased, reflecting increased antigen presentation, increased frequency of dengue virus-specific T lymphocytes in secondary infection, and more rapid activation and proliferation of memory T lymphocytes. Positive feedback effects of activated dengue virus-specific T lymphocytes on monocytes through the action of interferon-␥ further contribute to the dysregulation of cytokine production. However, the authors are conscious that, in the absence of an animal model of DHF/DSS, further clinical studies of patients with DHF/DSS will be needed to support or refute their model.
Laboratory diagnosis
A laboratory diagnosis of dengue infections can be accomplished by detecting either the virus or antidengue antibodies. Until recently, detection of the virus relied solely on viral isolation; however, current procedures can detect dengue virus RNA and specific virus antigens in fixed tissues. Circulating virus remains detectable in the blood during the febrile (viremic) period (in average, 5 days after onset of symptoms) and is rapidly cleared with the appearance of neutralizing antibodies [26] . Serum is the specimen of choice for both virologic and serologic studies. Even though mononuclear cells are the target cells for virus replication, a recent comparison among serum, buffy coat, and whole blood as clinical specimens performed in the authors' laboratory demonstrated that serum remains the best sample for viral detection by reverse transcription polymerase chain reaction (RT-PCR) (De Paula et al.: Journal of Virological Methods 2002, accepted for publication). Other researchers have found that polymerase chain reaction on the buffy coat was able to detect dengue in a false-negative sample [27] , and another study suggests an association of peripheral blood leukocytes (PBL)-RT-PCR with a serologic method to improve dengue diagnosis [28] . Viral isolation uses an established cell culture line derived from A. albopictus cells (C6/36 cells) followed by virus detection by an indirect immunofluorescence assay [29] . Other viral isolation systems include inoculation of samples from established mammalian cell culture lines (eg, LLC-MK2 cells), intrathoracic inoculation of mosquitoes, and intracranial inoculation of suckling mice. Because of the intrinsic complexity of mosquito inoculation and the low yield of mammalian cell cultures and suckling mouse inoculations, inoculation of C6/36 cells with acute serum samples is the method of choice for dengue virus isolation.
Serologic diagnosis depends on the presence of IgM antibodies or, less frequently, on a rise in IgG antibody titers in paired samples collected during the acute and convalescent stages of the disease. IgM antibodies against dengue are detected by an IgM-capture enzymelinked immunosorbent assay during the acute phase of the disease, and 90% of the patients are IgM-positive after the fifth day after onset of symptoms. These antibodies remain detectable for approximately 2 to 3 months after the beginning of the symptoms. Serology does not identify the infecting strain and needs at least 5 days of disease to yield a diagnosis, so RT-PCR has been used in several protocols because of its ability to detect virus bound to neutralizing antibodies and to type the infecting virus rapidly. RT-PCR might also detect small quantities of virus caused by low viremia or inadequate sample storage. However, RT-PCR must still be viewed as an experimental approach because a consensus has not been reached on the optimal standardization of each step of the procedure.
Management
There is no specific management available for dengue fever and DHF/DSS. Patients with dengue fever need oral fluids to replace fluid lost through diarrhea and vomiting, and analgesics and antipyretics for high fever (to avoid any impairment of the platelet function, acetaminophen is acceptable but aspirin is not) [30] . It is very important to follow up closely and to act promptly at signs that the disease is worsening. The World Health Organization has issued a document focusing on the guidelines for treatment of DHF/DSS in small hospitals [31] . These guidelines are easy to follow and can be used in any hospital until the patient is admitted to an ICU. The most important element of treatment of a patient with DSS is providing intensive care with close monitoring of blood pressure, hematocrit, platelet count, urinary output, hemorrhagic manifestations, and level of consciousness. With adequate and appropriate fluid replacement, DSS is rapidly reversible. Steroids are not helpful in the treatment of DSS [32, 33] .
Control of the disease
Controlling the vector is currently the only option for reducing dengue and DHF/DSS rates [34] . Mosquito population may be controlled either by the use of insecticides or by community participation in the reduction of sources of mosquito breeding [35] . The World Health Organization has developed a global strategy for prevention and control of dengue fever and DHF/DSS. Essential elements of this plan are integrated mosquito control with community involvement, disease and vector surveillance, emergency preparedness, personnel training, and applied research [36] .
Future prospects for the availability of a vaccine that affords protection against all four serotypes offer the promise of an additional intervention to combat the disease in hyperendemic areas [37] . Currently, there is no commercial vaccine available for dengue. A dengue vaccine must elicit sustained levels of neutralizing antibodies and provide long-lasting protection in all vaccinated people without posing any risk to their health either by producing adverse effects or by inducing low levels of antibodies capable of enhancing subsequent dengue infections. Attenuated dengue vaccines have been produced at Mahidol University in Thailand and tested in Thai volunteers in all formulations. The vaccines were found safe and immunogenic in both adults and children.
The master seeds of these vaccines were provided to Aventis Pasteur for testing and large-scale production [38] . These vaccines were combined into a tetravalent vaccine and tested in human volunteers. All tetravalent recipients were viremic with dengue-3 virus and developed neutralizing antibodies against dengue-3 virus. Although the authors report that the vaccine was safe and tolerable in humans, the preference for dengue-3 replication precludes its current use because of the fact that it could predispose vaccinated people to DHF/DDS [39•].
The use of molecular biology will allow the production of recombinant tetravalent dengue vaccines containing the most immunogenic proteins of all dengue serotypes. Several . Unfortunately, despite the efforts in manufacturing a tetravalent dengue vaccine, there has been no success in engineering a vaccine that will confer protection against all four dengue serotypes. However, a chimeric yellow fever dengue virus tetravalent vaccine has recently been successfully tested on nonhuman primates and will probably be tested in humans shortly [45••].
Conclusions
Because of the impact of dengue infections on public health, the strategies to control the disease should rely on vector and disease surveillance, community participation in reducing mosquito breeding sites, and early diagnosis and treatment of the severe cases while the long-overdue dengue vaccine is awaited. 
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